Adicet Bio Financial Results
Adicet Bio reported third quarter 2026 financial results and provided updates on its clinical pipeline, including positive Phase 1 data for prula-cel in systemic lupus erythematosus. The company ended the quarter with $204.4 million in cash and cash equivalents, providing a projected runway into the second half of 2027.
- Term
- Q3 2026
“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients.”
Chen Schor, President and Chief Executive Officer of Adicet Bio